NVO Preview Mode — Vezi un preview — analiza completa cu Strategy Signals, Smart Money 13F si Insider Trades disponibila cu cont. Sign Up Free → sau Login
📡 SignalRadar — RadarScope
Novo Nordisk A/S
NVO NYSE Healthcare Drug Manufacturers - General
$47.93
1M: +8.8% | 3M: +30.4%
Calitate
Q10
Risc
R3
Scor AI
50
Verdict
TINE
Market Cap
$213.0B
P/E Ratio
11.6
Profit Margin
37.2%
ROE
66.4%
📈 Earnings Report — 2026-05
Ultimul trimestru raportat
EPS Actual
$1.04
▲ 4.0% QoQ▲ 13.0% YoY
EPS Estimat
$0.87
Beat by 19.5%
Revenue Actual
$11.02B
▼ 11.8% QoQ▼ 4.1% YoY
Revenue Estimat
$10.86B
Beat by 1.5%
Istoric Ultimele 4 Trimestre
2026-05
EPS Actual
$1.04
EPS Est.
$0.87
Revenue
$11.02B
Beat/Miss
Beat by 19.5%
2026-02
EPS Actual
$1
EPS Est.
$0.9
Revenue
$12.50B
Beat/Miss
Beat by 11.1%
2025-11
EPS Actual
$1.02
EPS Est.
$0.77
Revenue
$11.78B
Beat/Miss
Beat by 32.5%
2025-08
EPS Actual
$0.97
EPS Est.
$0.93
Revenue
$12.13B
Beat/Miss
Beat by 4.3%
Urmatorul Raport
Data
2026-08-05
EPS Estimat
$0.82
Revenue Estimat
$11.06B
💰 Dividende Recente
2026-03
$1.217
Yield: 510.54%
Plata: 2026-04
2025-08
$0.584
Yield: 321.28%
Plata: 2025-08
2025-03
$1.143
Yield: 238.98%
Plata: 2025-04
2024-08
$0.517
Yield: 107.22%
Plata: 2024-08
📊 Scoruri Companie
Crestere 9/10
9
Revenue & Profit Growth
Evaluare 5/10
5
P/E · P/B · P/S
Calitate 10/10
10
Marje · ROE · Datorii
Risc 3/10
3
Beta · Market Cap
📈 Date Financiare Istorice in miliarde USD
💰 Revenue
📊 Net Profit
💵 Cash Flow
Operating (albastru) · Free (violet)
🏦 Cash & Datorii
Cash (verde) · Long-term Debt (rosu)
💸 Operating Expenses
🤖 Analiza RadarScope AI
Analiza indisponibila temporar.
💡 Vezi datele de mai jos
🐂 BULL CASE
Date financiare solide
Pozitie competitiva puternica
🐻 BEAR CASE
Evaluare ridicata
Incertitudine macro
TINE Analiza manuala recomandata
📊 Metrici Fundamentale
P/E TTM11.6
P/B TTM6.95
P/S TTM4.30
EV/EBITDA
Gross Margin81.8%
Operating Margin45.3%
Net Margin37.2%
ROE66.4%
ROA21.8%
Debt/Equity
Current Ratio0.79
FCF Yield2.2%
Dividend Yield3.7%
Beta0.35
💰 Venituri & Profit (ultimele trimestre)
TrimestruRevenueGross ProfitNet IncomeEPS
2025-12$309.1B$250.3B$102.4B$23.06
2024-12$290.4B$245.9B$101.0B$22.67
2023-12$232.3B$196.5B$83.7B$18.67
2022-12$177.0B$148.5B$55.5B$12.26
🏢 Profil Companie
CEOMaziar Mike Doustdar
Angajati77406
IPO1981-04-30
52W High$71.80
52W Low$35.12
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care di...
🎯 Score Breakdown
Calitate Companie (Q) 10/10
Risc Speculativ (R) 3/10
Scor AI RadarScope 50/100
VERDICT FINAL
TINE
Analiza manuala recomandata
🤖 Chat AI — Intreaba despre NVO
RadarScope AI
Buna! Pot raspunde la orice intrebare despre NVO. Ce vrei sa stii?

🔒 Analiza completa disponibila cu cont SignalRadar

Vezi Strategy Signals AI (Triple Oversold, BB Squeeze), Smart Money 13F ($837 mld Berkshire+BlackRock+Vanguard), Insider Trades live SEC Form 4, News + Short Interest in timp real, 20+ indicatori tehnici Multi-TF.

🚀 Cont Gratuit (25 tickere) Vezi planurile platite (de la $4.99)
+ 13F Smart Money+ Form 4 Insider+ TA MEGA 20+ indicatori+ AI Signals Triple Oversold etc.+ Multi-TF 1D/1W/1M
[!] Datele sunt informative. NU constituie sfat investitional personalizat. Decizia de investitie iti apartine. Detalii